Discover Novel Gene Therapy Delivery Routes to Effectively Target the CNS, Optimizing Preclinical Models to Confidently Translate into the Clinic & Mitigate Immunogenicity to Deliver an Efficacious Dose

Built with the field’s thought-leaders from the likes of Pfizer, Biogen, Voyager and Novartis, GTxN is the industry’s first and only meeting dedicated to solving your translational drug development challenges enabling you to accelerate the development of your neurological gene therapy candidate.